X4 Pharmaceuticals (XFOR) and taiba rare, a healthcare company, announced a strategic exclusive partnership for the distribution and commercialization of XOLREMDI in select Middle East countries, pending regulatory approvals.
XOLREMDI, approved by the U.S. FDA in April 2024, is the first oral treatment for WHIM syndrome, a rare primary immunodeficiency disorder.
WHIM syndrome, characterized by warts, hypogammaglobulinemia, infections, and myelokathexis, affects immune function by impairing neutrophil circulation.
Under the agreement, taiba rare will lead distribution, marketing, and sales in the MENA region (Middle East and North Africa).
Local regulatory filings will follow X4's U.S. FDA submission dossier, and XOLREMDI may be available for compassionate use before approvals.
This collaboration enhances X4's global reach, providing life-changing treatment options for WHIM syndrome patients in the region.
XFOR closed Tuesday's (Feb.18 2025) trading at $0.49 down by 1.97%. In premarket trading Wednesday the stock is up by 4.99% at $0.52.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.